cryptotanshinone has been researched along with Osteosarcoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bittner, M; Datta, A; Hua, J; Lopes, R; Miller, T; Sima, C; Vundavilli, H; Wilson-Robles, HM | 1 |
| Chuang, CJ; Huang, HS; Huang, ST; Yen, JH | 1 |
| Ji, Q; Wang, Y; Xu, Y; Zhang, Q | 1 |
3 other study(ies) available for cryptotanshinone and Osteosarcoma
| Article | Year |
|---|---|
Anti-tumor effects of cryptotanshinone (C
Topics: Adolescent; Apoptosis; Bone Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Osteosarcoma; Phenanthrenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Young Adult | 2022 |
Activation of dynamin-related protein 1 - dependent mitochondria fragmentation and suppression of osteosarcoma by cryptotanshinone.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Cell Cycle; Cell Proliferation; Dynamins; GTP Phosphohydrolases; Humans; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred NOD; Mice, SCID; Microtubule-Associated Proteins; Mitochondria; Mitochondrial Proteins; Osteosarcoma; Phenanthrenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
[Cryptotanshinone down-regulates the expression of VEGF and inhibits angiogenesis in U2OS osteosarcoma cells].
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Drugs, Chinese Herbal; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Microscopy, Fluorescence; Neovascularization, Pathologic; Neovascularization, Physiologic; Osteosarcoma; Phenanthrenes; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2016 |